Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Section 1 of 6

Terms and abbreviations

1 evidence topic · 0 sources

AbbreviationTerm
AAPAbiraterone acetate plus prednisone
ABIAbiraterone
ADTAndrogen deprivation therapy
AEAdverse event
AHFSAmerican Hospital Formulary Service
AMLAcute myeloid leukemia
APCAmbulatory payment classification
ARAndrogen receptor
AR-V7Androgen receptor splice variant 7
ARPIAndrogen receptor pathway inhibitor
ARTAAndrogen receptor-targeted agent
ASPAverage sales price
ATMAtaxia-telangiectasia mutated gene
AUCArea under the concentration-time curve
AWPAverage wholesale price
BCBreast cancer
BCRBiochemical recurrence
BCRPBreast cancer resistance protein
BICRBlinded independent central review
BIDTwice daily
BPABone-protecting agent
BPI-SFBrief Pain Inventory-Short Form
BRCABreast cancer susceptibility gene
cfDNACell-free DNA
CIConfidence interval
CMSCenters for Medicare & Medicaid Services
CNSCentral nervous system
CRComplete response
crPFSClinical or radiographic progression-free survival
CRPCCastration-resistant prostate cancer
CSPCCastration-sensitive prostate cancer
CTComputed tomography
CTBSComputed tomography plus bone scan
CTCAECommon Terminology Criteria for Adverse Events
ctDNACirculating tumor DNA
CYCalendar year
CYPCytochrome P450
DDIDrug-drug interaction
dMMRDeficient mismatch repair
DNADeoxyribonucleic acid
DORDuration of response
EAUEuropean Association of Urology
ECGElectrocardiogram
ECOGEastern Cooperative Oncology Group
eCQMElectronic clinical quality measure
EEDEmbryonic ectoderm development
eGFREstimated glomerular filtration rate
EMAEuropean Medicines Agency
ENZEnzalutamide
EOMEnhancing Oncology Model
EQ-5D-5LEuroQol five-dimension, five-level instrument
EREmergency room
EUEuropean Union
EZH1Enhancer of zeste homolog 1
EZH2Enhancer of zeste homolog 2
FACT-PFunctional Assessment of Cancer Therapy-Prostate
FDAFood and Drug Administration
FDRFirst-degree relative
GIGastrointestinal
GLPGood Laboratory Practice
GnRHGonadotropin-releasing hormone
H3K27me3Histone 3 lysine 27 trimethylation
HCPCSHealthcare Common Procedure Coding System
HCRUHealthcare resource utilization
HRHazard ratio
HRQoLHealth-related quality of life
HRRHomologous recombination repair
HRUHealthcare resource utilization
ibPFSImaging-based progression-free survival
IC50Half-maximal inhibitory concentration
ICERIncremental cost-effectiveness ratio
ICUIntensive care unit
INDInvestigational new drug application
INNInternational nonproprietary name
IQRInterquartile range
IUInternational unit
IVIntravenous
LCLung cancer
LNLymph node
LOTLine of therapy
MACMedicare Administrative Contractor
mCRPCMetastatic castration-resistant prostate cancer
mCSPCMetastatic castration-sensitive prostate cancer
MDSMyelodysplastic syndrome
MFPMaximum fair price
mHSPCMetastatic hormone-sensitive prostate cancer
MIPSMerit-based Incentive Payment System
MMRMismatch repair
mPCaMetastatic prostate cancer
MRMolecular response
MR50Molecular response of at least 50% reduction in ctDNA fraction
MR90Molecular response of at least 90% reduction in ctDNA fraction
MRIMagnetic resonance imaging
MSI-HMicrosatellite instability-high
NCINational Cancer Institute
NDCNational Drug Code
NENot estimable; neuroendocrine (by context)
NGSNext-generation sequencing
NHTNovel hormonal therapy
nmCRPCNonmetastatic castration-resistant prostate cancer
NRNot reached
NSCLCNon-small-cell lung cancer
OOPOut-of-pocket
ORRObjective response rate
OSOverall survival
PARPPoly(ADP-ribose) polymerase
PBMCPeripheral blood mononuclear cell
PCProstate cancer
PCaProstate cancer
PCWG3Prostate Cancer Clinical Trials Working Group 3
PD-1Programmed cell death protein 1
PD-L1Programmed death ligand 1
PETPositron emission tomography
PFSProgression-free survival
PKPharmacokinetics
PMPMPer member per month
POOral administration
PPPMPer patient per month
PPPYPer patient per year
PRPartial response
PRC2Polycomb repressive complex 2
PRO-CTCAEPatient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
PSPerformance status
PSAProstate-specific antigen
PSA50Decline in PSA of at least 50% from baseline
PSA90Decline in PSA of at least 90% from baseline
PSMAProstate-specific membrane antigen
QALYQuality-adjusted life-year
QDOnce daily
RADRadiographic progression
RCTRandomized controlled trial
RECISTResponse Evaluation Criteria in Solid Tumors
RLTRadioligand therapy
RP2DRecommended phase 2 dose
RP3DRecommended phase 3 dose
rPFSRadiographic progression-free survival
RWReal-world
SAESerious adverse event
SDStandard deviation
SECSecurities and Exchange Commission
SEERSurveillance, Epidemiology, and End Results Program
SoCStandard of care
SPMSecond primary malignancy
SRESkeletal-related event
SSESymptomatic skeletal event
TEAETreatment-emergent adverse event
TGITumor growth inhibition
TMB-HTumor mutational burden-high
TRAETreatment-related adverse event
TTPDTime to prostate-specific antigen progression or death
UCPUnequivocal clinical progression
UIUncertainty interval
USDUnited States dollars
VASVisual analog scale
WACWholesale acquisition cost
WHOWorld Health Organization
WTPWillingness to pay